Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437421 | 1.00 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL4168087 | 1.00 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL4178006 | 0.96 | — | — | |
| SCHEMBL5051935 | 0.79 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL3714910 | 0.73 | — | — | |
| SCHEMBL20104747 | 0.73 | TSHR (0.31) | TSHRCYP2C19 | |
| SCHEMBL9148805 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL4048738 | 0.71 | — | — | |
| SCHEMBL4441457 | 0.67 | — | — | |
| SCHEMBL31113476 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105256-A1 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2009-04-23 | — | — | US | claimed |
| JP-2007531766-A | — | — | 2007-11-08 | — | — | JP | claimed |
| EP-1729815-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | Cardiome Pharma Corp. (CA) | 2006-12-13 | — | — | EP | claimed |
| WO-2005113011-A2 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105256-A1 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CACNA1B, CACNA1F, KCNN2 | TSHR 3230/4885CYP2C19 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.